EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeting the IL ‐5 pathway in eosinophilic asthma: A comparison of anti‐ IL ‐5 versus anti‐ IL ‐5 receptor agents

David J Jackson iD, Michael E Wechsler, Guy Brusselle, Roland Buhl

Allergy · 2024-11 · 79 (11) · 2943-2952

DOI: 10.1111/all.16346 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Allergy, online erschienen am 12.10.2024. Verfasst von David J Jackson und 3 weiteren Autor:innen. Beteiligte Einrichtung: Guy's Severe Asthma Centre, Guy's and St Thomas' NHS Trust, London, UK. Hauptthemen laut MEDLINE: Interleukin-5, Asthma, Receptors, Interleukin-5, Anti-Asthmatic Agents. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Eosinophilic asthma is characterized by frequent exacerbations, poor symptom control and accelerated lung function decline. It is now recognized that the immune response underlying eosinophilic asthma involves a complex network of interconnected pathways from both the adaptive and innate immune systems. Within this response, interleukin‐5 (IL‐5) plays a central role in eosinophil differentiation, activation and survival and has emerged as a key target for therapies treating severe asthma. The monoclonal antibodies mepolizumab and reslizumab target the ligand IL‐5, preventing its interaction with eosinophils; in contrast, benralizumab binds to the IL‐5 receptor (IL‐5R), preventing IL‐5 from binding and leading to substantially greater eosinophil reduction by enhanced antibody‐dependent cell‐mediated cytotoxicity. Although no direct head‐to‐head clinical trials of asthma have been published to formally evaluate the clinical significance of these different therapeutic approaches, the potential benefits of partial versus complete eosinophil depletion continue to remain an important area of study and debate. Here, we review the existing real‐world and clinical study data of anti‐IL‐5/anti‐IL‐5R therapies in severe eosinophilic asthma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin-5AsthmaReceptors, Interleukin-5Anti-Asthmatic AgentsEosinophilsHumansSignal TransductionMolecular Targeted TherapyTreatment OutcomeAntibodies, Monoclonal, HumanizedEosinophiliaAntibodies, MonoclonalAnimals

Stichwörter der Autor:innen

IL‐5IL‐5Rasthmabenralizumabeosinophilmepolizumabreslizumab

Substanzen

Interleukin-5Receptors, Interleukin-5Anti-Asthmatic AgentsIL5 protein, humanAntibodies, Monoclonal, HumanizedAntibodies, Monoclonal

Autor:innen und Institutionen

  • Guy's Severe Asthma Centre, Guy's and St Thomas' NHS Trust, London, UK.
  • School of Immunology & Microbial Sciences, King's College London, London, UK.
  • Department of Medicine, National Jewish Health, Denver, Colorado, USA.
  • Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium.
  • Pulmonary Department, Mainz University Hospital, Mainz, Germany.

ORCID-Profile: David J Jackson

Förderung

  • AstraZeneca

Zitieren

APA

Jackson, D. J., Wechsler, M. E., Brusselle, G., & Buhl, R. (2024). Targeting the IL ‐5 pathway in eosinophilic asthma: A comparison of anti‐ IL ‐5 versus anti‐ IL ‐5 receptor agents. Allergy, 79(11), 2943-2952. https://doi.org/10.1111/all.16346

Vancouver

Jackson DJ, Wechsler ME, Brusselle G, Buhl R. Targeting the IL ‐5 pathway in eosinophilic asthma: A comparison of anti‐ IL ‐5 versus anti‐ IL ‐5 receptor agents. Allergy. 2024;79(11):2943-2952. doi:10.1111/all.16346

BibTeX
@article{Jackson2024,
  author = {Jackson, David J and Wechsler, Michael E and Brusselle, Guy and Buhl, Roland},
  title = {Targeting the IL ‐5 pathway in eosinophilic asthma: A comparison of anti‐ IL ‐5 versus anti‐ IL ‐5 receptor agents},
  journal = {Allergy},
  year = {2024},
  volume = {79},
  number = {11},
  pages = {2943--2952},
  doi = {10.1111/all.16346}
}
Kostenlos starten →